Magnesium%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520sulphate

# Magnesium Sulphate ## Overview Magnesium sulphate is an electrolyte that plays a vital role in numerous physiological processes, including nerve conduction, muscle contraction, cardiac function, and enzyme activity. It is available for intravenous (IV) and intramuscular (IM) administration. ## Primary Indications * Treatment of hypomagnesemia. * Management of eclampsia and pre-eclampsia. * Management of status epilepticus refractory to other agents. * Treatment of torsades de pointes. * Management of severe asthma exacerbations (adjunctive therapy). * Prevention and treatment of cardiac arrhythmias associated with hypomagnesemia. ## Adult Dosing * **Hypomagnesemia:** * **Severe (serum magnesium < 1 mg/dL):** 4 to 6 grams IV in divided doses over 24 hours, followed by a maintenance dose of 1 to 2 grams every 24 hours. * **Less severe (serum magnesium 1-1.5 mg/dL):** 1 to 2 grams IV or IM every 6 to 12 hours for 4 doses. * **Maintenance:** Doses may be adjusted based on serum magnesium levels and clinical response. * **Eclampsia/Pre-eclampsia:** Loading dose: 4 to 6 grams IV over 5 minutes. Maintenance infusion: 1 to 2 grams per hour IV. IM administration may be used for maintenance (e.g., 5 grams IM in each buttock every 4 hours). Dosing may vary based on institutional protocols. * **Status Epilepticus (refractory):** 2 to 6 grams IV infused slowly over 10 to 20 minutes. Dosing may be repeated. * **Torsades de Pointes:** 1 to 2 grams IV in 50-100 mL D5W infused over 5-10 minutes. May repeat. Higher doses can be given as an infusion (e.g., 5 grams in 1 L D5W over 1 hour). * **Severe Asthma (adjunctive):** 1 to 2 grams IV infusion over 15-30 minutes. ## Pediatric Dosing Dosing in children is highly variable and often based on weight and indication, with specific protocols varying by institution. * **Hypomagnesemia:** Typically 25 to 50 mg/kg/dose IV or IM every 4 to 6 hours for 4 doses. Higher doses may be necessary in severe cases. * **Eclampsia (adjunctive):** May follow adult protocols under close supervision. * **Status Epilepticus (refractory):** 25 to 50 mg/kg/dose IV infused slowly. * **Asthma (adjunctive):** 25 to 50 mg/kg/dose IV, maximum 2 grams. ## Dose Adjustments * **Renal Impairment:** Magnesium is renally excreted. In patients with significant renal impairment, doses should be reduced, and serum magnesium levels closely monitored to prevent accumulation and toxicity. Dosing adjustments should be guided by renal function tests (e.g., creatinine clearance). ## Contraindications * Myocardial damage. * Heart block. * Hypermagnesemia. * Shock. * Severe renal impairment (relative contraindication; use with extreme caution and reduced doses). * Myasthenia gravis (potential for neuromuscular blockade exacerbation). ## Adverse Effects Common side effects include flushing, warmth, sweating, nausea, vomiting, and hypotension. More serious adverse effects include: * **Neuromuscular blockade:** Deep tendon reflex depression, muscle weakness, respiratory depression, paralysis. * **Cardiovascular:** Bradycardia, hypotension, cardiac arrest, ECG changes (e.g., widened QRS complex, flattened T waves, prolonged PR interval). * **Central Nervous System:** Drowsiness, lethargy, confusion, hyporeflexia, decreased level of consciousness. * **Hypermagnesemia:** Can lead to any of the above effects, potentially progressing to coma and death. ## Key Drug Interactions * **Neuromuscular Blockers:** Magnesium can potentiate the neuromuscular blocking effects, leading to increased risk of respiratory depression and paralysis. * **Calcium Salts:** Concurrent administration can antagonize the effects of magnesium. * **Tetracyclines and Bisphosphonates:** Magnesium can decrease the absorption of these drugs. Administer at least 2 hours apart. * **Digoxin:** High doses of IV magnesium may increase digoxin toxicity. ## Monitoring * **Serum Magnesium Levels:** Monitor frequently, especially during loading doses and in patients with renal impairment. Target therapeutic levels vary by indication (e.g., 2-3.5 mg/dL for eclampsia, 4-7 mg/dL for torsades de pointes). * **Renal Function:** Monitor serum creatinine and creatinine clearance. * **Deep Tendon Reflexes:** Assess regularly, as decreased reflexes can indicate hypermagnesemia. * **Respiratory Rate and Effort:** Monitor for signs of respiratory depression. * **Blood Pressure and Heart Rate:** Monitor for hypotension and bradycardia. * **Urine Output:** Monitor for adequate renal function. * **ECG:** Monitor for cardiac conduction abnormalities, especially in patients receiving high doses or with pre-existing cardiac conditions. ## Clinical Pearls * Magnesium sulphate is a potent medication. Administration should be performed with caution and under appropriate monitoring. * When administering IV magnesium, ensure it is infused slowly to minimize the risk of hypotension and adverse effects. * In patients with severe hypomagnesemia, correction of magnesium should precede or occur concurrently with electrolyte correction (e.g., potassium). * Intramuscular (IM) administration is often painful; consider administering into a large muscle mass and possibly with lidocaine. * The risk of hypermagnesemia is significantly increased in patients with impaired renal function. *** *This information is intended for clinical professionals. Always consult the most current prescribing information and institutional protocols for definitive guidance.*